Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
174 stopped studies mapped to Intestinal Carcinoma and descendants · 93% state a reason
Over the 174 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05518032 | Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal… | Phase 2 | withdrawn | Aug 26, 2022 | Roswell Park Cancer Institute | prioritization of studies | Other (stated, no rule matched) |
| NCT05356897 | Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive… | Phase 2 | withdrawn | May 2, 2022 | Academic and Community Cancer Research United | no sites were regulatory ready and the SC took the study to a different group. | Other (stated, no rule matched) |
| NCT05450393 | Data Collection of PillCamTM SB3 Capsule Endoscopy and Device-Assisted Enteroscopy… | — | withdrawn | Jul 8, 2022 | Medtronic - MITG | Study was cancelled by sponsor due to priority realignment | Other (stated, no rule matched) |
| NCT05672342 | Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy… | Early Phase 1 | withdrawn | Jan 5, 2023 | City of Hope Medical Center | withdrawn | Other (stated, no rule matched) |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and… | Phase 2 | terminated | Feb 20, 2018 | M.D. Anderson Cancer Center | Project delays | Other (stated, no rule matched) |
| NCT03631641 | Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History… | Phase 2 | terminated | Aug 15, 2018 | John Hays | Sponsor decision | Sponsor / business decision |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | N/A | withdrawn | Jul 22, 2022 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT03300544 | Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating… | Phase 1 | terminated | Oct 3, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT05648006 | First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer | Phase 2 | terminated | Dec 13, 2022 | Binhui Biopharmaceutical Co., Ltd. | Strategy adjustment | Sponsor / business decision |
| NCT05900648 | Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With… | Phase 2 | withdrawn | Jun 12, 2023 | M.D. Anderson Cancer Center | 0 participant accrual | Enrollment / accrual |
| NCT04808362 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid…(MYCure) | Phase 1 / Phase 2 | terminated | Mar 22, 2021 | Peptomyc S.L. | Phase 1completed; sponsor decided to change strategy to a combination study | Sponsor / business decision |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | Phase 1 | suspended | Jan 20, 2021 | DNAtrix, Inc. | DNAtrix management decision not based on study design, safety, or site performance. | Safety / toxicity |
| NCT02293811 | Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant…(P2RX7) | N/A | terminated | Nov 18, 2014 | Centre Hospitalier Universitaire de Nice | the tissue mass of each biopsy sample was not sufficient to perform an exploratory analysis to… | Other (stated, no rule matched) |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or… | Phase 1 / Phase 2 | terminated | Dec 18, 2017 | Georgetown University | Study closed due to lack of enrollment. | Enrollment / accrual |
| NCT01913275 | Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage… | N/A | withdrawn | Aug 1, 2013 | All India Institute of Medical Sciences | Lack of interest | Other (stated, no rule matched) |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive… | Early Phase 1 | withdrawn | May 3, 2021 | Roswell Park Cancer Institute | Issues recruiting | Enrollment / accrual |
| NCT04054752 | Vaccine Response With NT-I7 | Phase 1 | withdrawn | Aug 13, 2019 | National Cancer Institute (NCI) | No subjects enrolled. | Enrollment / accrual |
| NCT01545141 | Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer | Phase 1 / Phase 2 | terminated | Mar 6, 2012 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT03592641 | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal… | Phase 2 | terminated | Jul 19, 2018 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT00745134 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating… | Phase 2 | terminated | Sep 3, 2008 | M.D. Anderson Cancer Center | The trial was stopped early because there was only one patient with pCR among the first 15 patients… | Other (stated, no rule matched) |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal… | Phase 2 | terminated | Aug 26, 2019 | M.D. Anderson Cancer Center | Due to Issues Enrolling Patients | Enrollment / accrual |
| NCT00303628 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III… | Phase 3 | terminated | Mar 17, 2006 | ECOG-ACRIN Cancer Research Group | The study was terminated before reaching its accrual goal due to slow accrual. | Enrollment / accrual |
| NCT04348916 | Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With… | Phase 1 | terminated | Apr 16, 2020 | Oncorus, Inc. | Terminated due to Oncorus portfolio reprioritization | Sponsor / business decision |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch…(REFIT-MSS) | Phase 2 | withdrawn | Oct 17, 2022 | Translational Research in Oncology | Study never started/ will not proceed. | Other (stated, no rule matched) |
| NCT04044430 | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E… | Phase 1 | terminated | Aug 5, 2019 | University of California, San Francisco | Sponsor funding | Funding |
| NCT05368688 | Microbiome in Colorectal Cancer Onset and Progression | — | terminated | May 10, 2022 | Viome | Recruitment rate was too low to continue the study. | Enrollment / accrual |
| NCT05291988 | A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural… | N/A | terminated | Mar 23, 2022 | Fred Hutchinson Cancer Center | Terminated due to low accrual | Enrollment / accrual |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | Phase 2 | terminated | Oct 3, 2018 | Abramson Cancer Center at Penn Medicine | Terminated due to slow enrollment and lack of efficacy | Efficacy / futility |
| NCT03781778 | Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors | Phase 2 | terminated | Dec 20, 2018 | Fred Hutchinson Cancer Center | Terminated due to expiration of funding | Funding |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies… | Phase 1 / Phase 2 | terminated | Oct 25, 2021 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid… | Phase 1 / Phase 2 | terminated | Mar 14, 2019 | Calithera Biosciences, Inc | Slow Enrollment | Enrollment / accrual |
| NCT04119830 | Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable… | Phase 2 | withdrawn | Oct 8, 2019 | Roswell Park Cancer Institute | implementation issues | Other (stated, no rule matched) |
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From… | Phase 1 | terminated | Jan 27, 2011 | Fox Chase Cancer Center | This study was closed early by the DSMB due to increased toxicity. | Safety / toxicity |
| NCT03050814 | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With… | Phase 2 | terminated | Feb 13, 2017 | National Cancer Institute (NCI) | Terminated after an unplanned interim efficacy analysis. | Efficacy / futility |
| NCT04499352 | A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have… | Phase 2 | withdrawn | Aug 5, 2020 | Boehringer Ingelheim | Not due to safety reasons (sponsor decision). | Safety / toxicity |
| NCT04418895 | Neoadjuvant Therapy for Localized Rectal Adenocarcinoma | Phase 2 | withdrawn | Jun 5, 2020 | UNC Lineberger Comprehensive Cancer Center | lack of resources | Other (stated, no rule matched) |
| NCT02319304 | Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed…(GCC 1314) | Phase 2 | terminated | Dec 18, 2014 | University of Maryland, Baltimore | Slow accrual, PI left instituion | Investigator |
| NCT04831827 | Promoting Equity for Cancer Screening and Follow-up | N/A | withdrawn | Apr 5, 2021 | Mayo Clinic | Insufficient study resources and change in practice. | Other (stated, no rule matched) |
| NCT04311047 | Preoperative Detection of Lymph Node Metastases in Pancreatic and Periampullary Carcinoma…(NANO-PANC) | N/A | terminated | Mar 17, 2020 | Radboud University Medical Center | We decided to stop inclusions and start analysis after 26 inclusions. | Other (stated, no rule matched) |
| NCT03280277 | Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal… | Early Phase 1 | terminated | Sep 12, 2017 | OHSU Knight Cancer Institute | low accrual | Enrollment / accrual |
| NCT03337776 | Effect of WhatsApp Messenger on Uptake of CRC Screening Study | N/A | withdrawn | Nov 9, 2017 | Chinese University of Hong Kong | COVID | COVID-19 / pandemic |
| NCT03942900 | Immunomonitoring and Biomarker Research in Patients With Squamous Cell Anal Carcinoma(LAND) | — | withdrawn | May 8, 2019 | Centre Hospitalier Universitaire de Besancon | Study not submitted to regulatory authorities | Other (stated, no rule matched) |
| NCT03137706 | Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or… | — | terminated | May 3, 2017 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | Phase 1 / Phase 2 | withdrawn | Jul 5, 2018 | University of Southern California | No funding | Funding |
| NCT03563352 | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in… | — | withdrawn | Jun 20, 2018 | University of Southern California | Zero accrual | Enrollment / accrual |
| NCT03257332 | Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After…(EDFI-Cohort) | — | withdrawn | Aug 22, 2017 | Slagelse Hospital | Not possible to include participants | Other (stated, no rule matched) |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic… | Phase 1 | terminated | May 2, 2016 | M.D. Anderson Cancer Center | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Sep 26, 2024source: clinicaltrials